uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma
Show others and affiliations
2014 (English)In: Acta neuropathologica communications, ISSN 2051-5960, Vol. 2, 174Article in journal (Refereed) Published
Abstract [en]

TP53 mutations confer subgroup specific poor survival for children with medulloblastoma. We hypothesized that WNT activation which is associated with improved survival for such children abrogates TP53 related radioresistance and can be used to sensitize TP53 mutant tumors for radiation. We examined the subgroup-specific role of TP53 mutations in a cohort of 314 patients treated with radiation. TP53 wild-type or mutant human medulloblastoma cell-lines and normal neural stem cells were used to test radioresistance of TP53 mutations and the radiosensitizing effect of WNT activation on tumors and the developing brain. Children with WNT/TP53 mutant medulloblastoma had higher 5-year survival than those with SHH/TP53 mutant tumours (100% and 36.6%±8.7%, respectively (p<0.001)). Introduction of TP53 mutation into medulloblastoma cells induced radioresistance (survival fractions at 2Gy (SF2) of 89%±2% vs. 57.4%±1.8% (p<0.01)). In contrast, beta-catenin mutation sensitized TP53 mutant cells to radiation (p<0.05). Lithium, an activator of the WNT pathway, sensitized TP53 mutant medulloblastoma to radiation (SF2 of 43.5%±1.5% in lithium treated cells vs. 56.6±3% (p<0.01)) accompanied by increased number of gammaH2AX foci. Normal neural stem cells were protected from lithium induced radiation damage (SF2 of 33%±8% for lithium treated cells vs. 27%±3% for untreated controls (p=0.05). Poor survival of patients with TP53 mutant medulloblastoma may be related to radiation resistance. Since constitutive activation of the WNT pathway by lithium sensitizes TP53 mutant medulloblastoma cells and protect normal neural stem cells from radiation, this oral drug may represent an attractive novel therapy for high-risk medulloblastomas.

Place, publisher, year, edition, pages
2014. Vol. 2, 174
National Category
Cancer and Oncology
URN: urn:nbn:se:uu:diva-262220DOI: 10.1186/s40478-014-0174-yPubMedID: 25539912OAI: oai:DiVA.org:uu-262220DiVA: diva2:852792
Available from: 2015-09-10 Created: 2015-09-10 Last updated: 2015-09-10Bibliographically approved

Open Access in DiVA

fulltext(2438 kB)30 downloads
File information
File name FULLTEXT01.pdfFile size 2438 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Baskin, Berivan
By organisation
Department of Immunology, Genetics and Pathology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 30 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 206 hits
ReferencesLink to record
Permanent link

Direct link